Cipla Ltd. Set to Launch Novel Synchrobreathe Inhaler for Obstructive Airway Disease

Cipla Ltd. Set to Launch Novel Synchrobreathe Inhaler for Obstructive Airway Disease

Cipla Ltd., an Indian multinational pharmaceutical and biotechnology company headquartered in Mumbai, India, has announced it is set to launch a novel inhaler designed to effectively manage Obstructive Airway Disease (OAD). The inhaler, called Synchrobreathe, is a breath-actuated inhaler (BAI) with a dose counter. This innovative medication delivery method was presented at the recently concluded South Africa Thoracic Society (SATS) Conference in Cape Town to over 200 healthcare providers and specialists.

The inhaler is user friendly and does not require good coordination from patients, which is frequently an issue with traditional pressurized, metered dose inhalers (pMDIs). In addition, the device does not require much inspiratory flow in order to function, an ideal feature for patients who are elderly, very young, or who are already in a state of severe disease. Medication adherence is also improved through its built-in dose counter.

Frank Pieters, Global Head of Respiratory, Cipla said, “Simple and intuitive, Synchrobreathe is an innovation in managing respiratory disease. Synchrobreathe is attractive for patients as the inhaler is easy to use effectively. Equally importantly, Synchrobreathe will help cut the time healthcare providers need to spend to train patients in correct inhaler use. With this simple inhaler, the healthcare professional knows the patient will be able to use it easily and get the full benefit from every dose.”

Paul Miller, Chief Executive Officer, Cipla Medpro, South Africa added, “South Africa has amongst the highest asthma mortality rates in the world. As a leading company in the area of respiratory health in South Africa, we are proud to announce the development of this innovation for the first time to the medical community at the SATS congress. Synchrobreathe will definitely make patients’ lives easier in managing their OAD. Synchrobreathe is in line with Cipla’s commitment to bring innovative products and inhalers to best fit physicians’ and patients’ needs, thereby advancing healthcare for all. Synchrobreathe is expected to reach the market in the current year.”

In other COPD-related news, researchers at Georgia State University say their findings, published July 14 in the International Journal of Nanomedicine, suggest their nano engineered vaccine induces long-term protection against respiratory syncytial virus (RSV) and could be a novel treatment option for this disease.

Leave a Comment